GH
Guardant Health Inc
$153.43-8.99%
Setup
No setup
Buy Zone
$156.56-$164.39
Sector
Diagnostics & Research
Industry
Diagnostics & Research
56
Recommendation
Avoid
Avoid
Too many CANSLIM criteria failing.
GH chart
Loading chart…
ADX
Strong47.9Long Term
Up ↑Intermediate Term
Up ↑Short Term
Up ↑Overall Quality56
RS Rating
90
relative strength
Fundamentals
40
Weak fund-Q
Volume Demand
68
+115% vs avg
Technical Setup
38
3/8 checks
Industry/Theme
91
Diagnostics & Research
Trade Plan
Avoid
Entry
$156.56
Entry Zone
$156.56-$164.39
Stop / Risk
$144.04
RS Rating
90
Volume confirmed
No
Targets
$187.87 / $195.7
Breakout · IBD Setup
3 ✓ 5 ✗
Entry $156.56–$164.39Stop $144.04Target $187.87 / $195.7
Market regimeRange
Quality56
RS Rating90
Above 50-MA-9.57%
Above 200-MA+16.62%
VolumeWeak
In Buy ZoneNo
Not extendedOK
Invalidation · Close below stop
How this came together
56
MarketRange
SetupNo setup
ConfidenceExperimental · not backtested
Fund-Q40 · Weak
StatusAvoid
Stock Data
52-Week Range75 – 191
Price % Chg YTD50.22%
Price % Chg 4wk-8.85%
50-Day Avg Vol1.9 Mil
P/E Ratio—
Market Cap$24B
SectorHealthcare
IndustryDiagnostics & Research
Company Fundamentals
EPS % Chg (Qtr)-12.34%
Sales % Chg (Qtr)44.33%
EPS Growth 5y-4.99%
Sales Growth 5y27.92%
Annual ROE—
Gross Margin65.01%
Operating Margin-39.7%
Net Margin-38.33%
Debt / Equity—
Setup levels
Current price
$153.43
Pivot
$156.56
Distance to buy
-19.7%
52-week range
74.55-191.05
Trigger evidence
No active trigger evidence available.
Financial health checks
1/3
Net margin above 10%
Net margin -38.33%
EPS growing quarter on quarter
EPS q/q -12.34%
Sales growing quarter on quarter
Sales q/q 44.33%
Key metrics
Finviz snapshot · value vs. sector median (≥5 peers)
Annual ROE—
Net margin-38.33%
vs sector -56.0%
Gross margin65.01%
vs sector -2.2%
EPS growth q/q-12.34%
vs sector -19.9%
Sales growth q/q44.33%
vs sector +25.6%
Debt / equity—
lower is better
Business quality
40
GradeWeak
EPS rating21
P/E—
Market cap$24B
IndustryDiagnostics & Research
Technical checks
Über 50-MA
Fail
Über 200-MA
Pass
RS-Linie auf neuem Hoch
Fail
Volumen bestätigt
Fail
In Kaufzone
Fail
Nicht überextended
Pass
Über 21-EMA
Fail
Volumen gesund
Pass
IBD / source mentions
No recent IBD mention found for this ticker.
Signal history
Added to list
2026-11-05
Trigger date
—
Days on list
1
Data sources: internal CANSLIM engine · Finviz snapshot · TradingView chart. Not investment advice.